Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 28, Number 9—September 2022
Research Letter

Social and Behavioral Factors Associated with Lack of Intent to Receive COVID-19 Vaccine, Japan

Takeshi ArashiroComments to Author , Yuzo Arima, Ashley Stucky, Chris Smith, Martin Hibberd, Koya Ariyoshi, and Motoi Suzuki
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (T. Arashiro, Y. Arima, A. Stucky, M. Suzuki); London School of Hygiene and Tropical Medicine, London, UK (T. Arashiro, C. Smith, M. Hibberd); Nagasaki University, Tokyo (T. Arashiro, C. Smith, M. Hibberd, K. Ariyoshi, M. Suzuki)

Suggested citation for this article

Abstract

Persons in Japan who did not intend to receive COVID-19 vaccines after widespread rollout were less likely than others to engage in preventive measures or to be afraid of getting infected or infecting others. They were also not less likely to engage in potentially high-risk behaviors, suggesting similar or higher exposure risks.

COVID-19 vaccines have become a critical tool in pandemic control (1). In Japan, BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com), mRNA-1273 (Moderna, https://www.modernatx.com), and ChAdOx1 nCoV-19 (AZD1222; Oxford/AstraZeneca, https://www.astrazeneca.com) have been approved, but use of ChAdOx1 nCoV-19 has been minimal. For the Omicron variant, 2 doses of mRNA vaccines might not be highly protective against symptomatic infection, but early data suggest they are still highly protective against severe disease and that a booster dose provides further protection (24). Addressing persons at highest risk for severe or fatal COVID-19 who do not intend to be vaccinated has become paramount as we transition to the endemic phase, which is especially true in Japan because most persons are not protected by natural infection (5). Several studies have addressed reasons behind this hesitancy at the early stage of vaccine rollout (69), but evidence on attitudes toward risk for infection and prevention and risk behaviors is scarce.

We retrospectively analyzed an online survey about life during the COVID-19 pandemic conducted by a marketing research company in Japan during November 26–28, 2021, after the vaccine rollout had stabilized and 70% of the population had received 2 doses. The total number of survey participants was 2,500 (250 participants for each sex and 10-year age group, 20–60 years of age) (Appendix). We extracted sociodemographic information, vaccination status (choices included vaccinated once, vaccinated twice, unvaccinated with intention to be vaccinated, unvaccinated without intention to be vaccinated, and prefer not to answer), attitudes toward COVID-19-related issues (e.g., whether participants were afraid of getting infected), and behaviors in the previous week (e.g., preventive measures such as mask-wearing and potentially high-risk behaviors such as visiting bars or restaurants) (10). For vaccination status, we categorized the first 3 options into vaccinated or intend to be vaccinated and the last 2 choices into no intention to be vaccinated, because persons who preferred not to answer likely did not intend to be vaccinated but were unwilling to disclose this information. Depending on the social or behavioral factor, we adjusted for potential confounders that were determined a priori (69). This study was reviewed and exempt from ethics approval by the Institutional Review Board of the National Institute of Infectious Diseases, Japan.

Overall, 2,069 (82.8%) participants had received 2 doses, 35 (1.4%) had received 1 dose, 95 (3.8%) were not vaccinated but intended to be, 203 (8.1%) had no intention of being vaccinated, and 98 (3.9%) preferred not to answer. By age group, proportions of vaccinated persons were similar to those in the general population of Japan (Appendix). The proportions of participants residing in each geographic region were also similar to the national distribution (Appendix). Compared with men 60–69 years of age, men 20–39 years of age, as well as women 20–40 years of age, were >2-fold more likely to have no intention of being vaccinated (Appendix Table 1). Persons who did not intend to be vaccinated were less likely to be afraid of getting infected (adjusted odds ratio [aOR] 2.32, 95% CI 1.53–3.53), family members getting infected (aOR 2.50, 95% CI 1.68–3.71]), infecting others (aOR 2.58, 95% CI 1.73–3.84), and bed shortages caused by a surge in severe COVID-19 cases (aOR 1.89, 95% CI 1.25–2.87). Persons who did not intend to be vaccinated also did not plan to receive a third (booster) dose, but 74% of persons who had received or intended to receive vaccines also intended to receive a booster dose. Persons without intention to be vaccinated were more likely to report not wearing a mask (aOR 2.01, 95% CI 1.52–2.65) and not using hand sanitizer (aOR 1.90, 95% CI 1.47–2.47) in the previous week. These persons were less likely to have gone shopping for nonessential goods in the past week (aOR 0.70, 95% CI 0.51–0.97), but no association was seen between vaccination intent and refraining from meeting with others (aOR 1.20, 95% CI 0.87–1.65) or going to crowded places or traveling (aOR 1.11, 95% CI 0.83–1.47). We also saw no association between vaccination intent and meeting noncohabitating friends, acquaintances, or family members (aOR 0.73, 0.47–1.12); dining out (aOR 0.92, 0.65–1.30); going out socially (aOR 0.87, 0.59–1.27); traveling (aOR 0.51, 0.22–1.22); or going to a gym (aOR 1.08, 0.64–1.83). We obtained similar results when we excluded persons who preferred not to answer regarding their vaccination status.

Persons who did not intend to receive COVID-19 vaccines were less likely to engage in preventive measures or be afraid of getting infected or infecting others, but we observed no association between vaccine intention and engaging in potentially high-risk behaviors. These results suggest that these nonintenders have similar or higher exposure risks compared with vaccinees and intenders. Similar surveys might be considered in other countries to understand vaccine denial and inform policies and risk communication.

Limitations of our study include selection bias and recall bias. Social desirability bias might be an issue, but this survey about life during the pandemic was not administered as an assessment about COVID-19 vaccination intent.

Dr. Arashiro is a research scientist in the Center for Surveillance, Immunization, and Epidemiologic Research at the National Institute of Infectious Diseases, Tokyo, Japan (joint appointment with the Department of Pathology), and a student in the joint PhD program at the London School of Hygiene and Tropical Medicine and Nagasaki University. His research interests include infectious diseases (especially emerging and reemerging infectious diseases) and global health.

Top

Acknowledgments

We thank the marketing research company for providing the original survey data.

This work was supported in part by a grant from the Japan Agency for Medical Research and Development (AMED) (grant no. JP21fk0108612) and the Nagasaki University WISE Programme.

Top

References

  1. World Health Organization. Coronavirus disease (COVID-19) pandemic [cited 2022 Jun 5]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  2. Andrews  N, Stowe  J, Kirsebom  F, Toffa  S, Rickeard  T, Gallagher  E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:153246. DOIPubMedGoogle Scholar
  3. Tseng  HF, Ackerson  BK, Luo  Y, Sy  LS, Talarico  CA, Tian  Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. [Erratum in: Nat Med. 2022;28:1095]. Nat Med. 2022;28:106371. DOIPubMedGoogle Scholar
  4. United Kingdom Health Security Agency. COVID-19 vaccine surveillance reports [cited 2022 Jun 5]. https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports
  5. Dong  E, Du  H, Gardner  L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:5334. DOIPubMedGoogle Scholar
  6. Nomura  S, Eguchi  A, Yoneoka  D, Kawashima  T, Tanoue  Y, Murakami  M, et al. Reasons for being unsure or unwilling regarding intention to take COVID-19 vaccine among Japanese people: A large cross-sectional national survey. Lancet Reg Health West Pac. 2021;14:100223. DOIPubMedGoogle Scholar
  7. Yoda  T, Katsuyama  H. Willingness to receive COVID-19 vaccination in Japan. Vaccines (Basel). 2021;9:48. DOIPubMedGoogle Scholar
  8. Machida  M, Nakamura  I, Kojima  T, Saito  R, Nakaya  T, Hanibuchi  T, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines (Basel). 2021;9:210. DOIPubMedGoogle Scholar
  9. Okubo  R, Yoshioka  T, Ohfuji  S, Matsuo  T, Tabuchi  T. COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines (Basel). 2021;9:662. DOIPubMedGoogle Scholar
  10. Arashiro  T, Arima  Y, Muraoka  H, Sato  A, Oba  K, Uehara  Y, et al. Behavioral factors associated with SARS-CoV-2 infection in Japan. Influenza Other Respir Viruses. 2022;irv.12992.

Top

Figure

Top

Suggested citation for this article: Arashiro T, Arima Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, et al. Social and behavioral factors associated with lack of intent to receive COVID-19 vaccine, Japan. Emerg Infect Dis. 2022 Sep [date cited]. https://doi.org/10.3201/eid2809.220300

DOI: 10.3201/eid2809.220300

Original Publication Date: July 06, 2022

Table of Contents – Volume 28, Number 9—September 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Takeshi Arashiro, Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo 162-8640, Japan

Send To

10000 character(s) remaining.

Top

Page created: June 30, 2022
Page updated: July 06, 2022
Page reviewed: July 06, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external